Lipocine Inc.

NASDAQ:LPCN

6.08 (USD) • At close November 1, 2024
Bedrijfsnaam Lipocine Inc.
Symbool LPCN
Munteenheid USD
Prijs 6.08
Beurswaarde 32,515,475
Dividendpercentage 0%
52-weken bereik 2.35 - 11.79
Industrie Biotechnology
Sector Healthcare
CEO Dr. Mahesh V. Patel Ph.D.
Website https://www.lipocine.com

An error occurred while fetching data.

Over Lipocine Inc.

Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline

Vergelijkbare Aandelen

Assembly Biosciences, Inc. logo

Assembly Biosciences, Inc.

ASMB

16.89 USD

aTyr Pharma, Inc. logo

aTyr Pharma, Inc.

LIFE

1.9 USD

SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc.

SABS

3.88 USD

Miromatrix Medical Inc. logo

Miromatrix Medical Inc.

MIRO

3.39 USD

Wave Life Sciences Ltd. logo

Wave Life Sciences Ltd.

WVE

13.83 USD

Vigil Neuroscience, Inc. logo

Vigil Neuroscience, Inc.

VIGL

3.87 USD

Clearside Biomedical, Inc. logo

Clearside Biomedical, Inc.

CLSD

1.01 USD

Eliem Therapeutics, Inc. logo

Eliem Therapeutics, Inc.

ELYM

5.11 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)